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Abstract
Background: Methotrexate (MTX) uptake is mediated by the reduced folate carrier (RFC). Defective
drug uptake in association with decreased RFC expression is a common mechanism of MTX resistance in
many tumor types. Heavy promoter methylation was previously identified as a basis for the complete
silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription
regulation are, however, not widely studied.
Methods: In the current study, RFC promoter methylation was assessed using methylation specific PCR
in a panel of malignant cell lines (n = 8), including MDA-MB-231, and M805, a MTX resistant cell line
directly established from the specimen of a patient with malignant fibrohistocytoma, whom received
multiple doses of MTX. A quantitative approach of real-time PCR for measuring the extent of RFC
promoter methylation was developed, and was validated by direct bisulfite genomic sequencing. RFC
mRNA levels were determined by quantitative real-time RT-PCR and were related to the extent of
promoter methylation in these cell lines.
Results: A partial promoter methylation and RFC mRNA down-regulation were observed in M805. Using
the quantitative approach, a reverse correlation (correlation coefficient = -0.59, p < 0.05) was identified
between the promoter methylation and RFC mRNA levels in this a panel of malignant cell lines.
Conclusion: This study further suggests that promoter methylation is a potential basis for MTX
resistance. The quantitative correlation identified in this study implies that promoter methylation is
possibly a mechanism involved in the fine regulation of RFC transcription.
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Methotrexate (MTX) remains an important drug in the
treatment of a variety of malignancies, such as acute lym-
phocytic leukemia (ALL), choriocarcinoma, non-Hodg-
kin's lymphoma, osteosarcoma, breast cancer, and head
and neck cancer. The mechanisms of MTX resistance
include: 1) impaired drug transport; 2) reduced drug accu-
mulation because of decreased MTX polyglutamylation or
increased drug hydrolysis; 3) increased drug efflux possi-
bly mediated by multiple drug resistance associated pro-
teins (MRPs); 4) alterations in the structure or expression
of the target enzyme dihydrofolate reductase (DHFR) and
some novel mechanisms proposed recently [1-3]. MTX is
delivered into cells predominantly via the reduced folate
carrier (RFC), a bi-directional anion exchanger with 12
putative transmembrane domains [4]. To generate suffi-
cient intracellular MTX, RFC transport of MTX is critical to
its efficacy. Since the human RFC cDNA was cloned in
1995 [5-8], intensive efforts have been made to explore its
clinical relevance in different tumor models. MTX resist-
ance has been associated with decreased expression of
RFC or loss of function of the carrier in many tumor types
[9-12]. The RFC is ubiquitously expressed in normal tis-
sues [13]; its regulatory mechanisms are, however, not
clearly understood. Transcription of the RFC starts from at
least four distinct promoters, (designated A, B, C, and D)
[14], and is complicated by multiple 5'-non-coding exons
resulting from alternative splicing [13,15-20]. The RFC
promoter B appeared to be most potent in activity, and
was predominantly utilized in tumor cells [16,19]. At least
18 different RFC transcripts have been reported, the func-
tions of which are not clear, although links to tissue spe-
cific expression were suggested [13]. Further information
on RFC regulation is of importance for understanding the
mechanisms of MTX resistance in these diseases.
DNA methylation plays an important role in embryonic
development and gene imprinting [21]. In cancer cells,
DNA methylation in the promoter region is often
involved in gene silencing, particularly for some tumor
suppressor genes [22]. Recently, it was reported that a
~1400 bp region, including RFC promoter B and A, was
identified as a CpG island [23]. Moreover, heavy pro-
moter methylation was the underlying mechanism for the
complete lack of RFC expression in MDA-MB-231 breast
cancer cell line [24], associated with MTX resistance [23].
However, the role and prevalence of promoter methyla-
tion in RFC are not widely studied. A study was therefore
initiated to further investigate the role of promoter meth-
ylation in a panel of malignant cell lines.
Methods
Cell Culture
The M805 cell line was directly established from a patient
with malignant fibrohistocytoma (MFH), who was treated
at Memorial Sloan-Kettering Cancer Center (MSKCC) and
received multiple courses of chemotherapy, including
MTX [25]. The fibrosarcoma cell line, HT1080; breast can-
cer cell lines MDA-MB-231, MCF-7; and leukemia cell line
CCRF-CEM were purchased from ATCC (Rockville, MD).
The MTX resistant leukemia cell line CEM-T and HL60R
have been described previously [26,27]. The MTX resistant
cell line, M316, was established from a relapsed pre-B ALL
patient at MSKCC. Cells were maintained as monolayer or
suspension in MEM-α media, supplemented with 10%
fetal calf serum (Life technologies, Bethesda, MD), 100
units/ml penicillin and 3 mg/ml streptomycin at 37°C in
a humidified atmosphere with 5% CO2.
MTX Uptake, Polyglutamylation and Cytotoxicity Assays
[3',5',7-3H] MTX was purchased from Moravek (Brea, CA).
MTX polyglutamate standards containing one to five addi-
tional glutamate residues were obtained from B. Schircks
Labs (Jona, Switzerland). MTX uptake and intracellular
MTX polyglutamtes were measured as described previ-
ously [27]. Non-labeled MTX was purchased from Sigma
(St. Louis, MO) and trimetrexate (TMTX) was obtained
from Warner Lambert/Parke-Davis (Ann Arbor, MI). Cell
growth inhibition studies with MTX and TMTX were per-
formed as described previously [27]. The fibrosarcoma
cell line, HT1080, was used as a control in the MTX trans-
port assays and cytotoxicity assays.
Analysis of hRFC Transcripts
Total RNA was isolated using UltraspecRNA reagent (Bio-
tecx, Houston, TX) according to manufacturer's instruc-
tions and was reverse-transcribed using Superscript II RT
(Invitrogen, Bethesda, MD). The level of RFC mRNA was
measured as described previously using quantitative real-
time RT-PCR [28]. For M805 cells, the RFC mRNA was
measured before and after the treatment with 5-aza-2'-
deoxycytidine (Sigma, St. Louis, MO) at a concentration
of 1 μM for 4 days, respectively. To screen for mutations
in the RFC, cDNA from the M805 cell line was PCR-ampli-
fied using four pairs of overlapping primers spanning the
entire coding region of RFC as described previously [29].
PCR products were gel-purified and subjected to auto-
mated sequencing on an ABI3100 sequencer (Applied
Biosystems, Foster City, CA), or manual sequencing with
a T7 Sequenase version 2.0 sequencing kit (Amersham,
Piscataway, NJ) in both directions.
Transfection of hRFC cDNA
The transfection of the full-length human RFC cDNA into
the RFC null, MDA-MB-231 cells was carried out with a
SuperFect Transfection Reagent Kit (Qiagen, Valencia CA)
according to manufacturer's instructions as described pre-
viously [30]. Stable transfection was obtained by selection
with zeocin (Invitrogen, Carlsbad, CA) at a concentration
of 400 μg for 2 weeks. Zeocin resistant colonies werePage 2 of 9
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real-time RT-PCR.
Methylation Specific PCR (MSP)
Genomic DNA was extracted using a QIAamp DNeasy Tis-
sue Kit (Qiagen, Valencia, CA) according to manufac-
turer's instructions.
Bisulfite treatment was carried out as described previously
[23]. Modified DNA was PCR-amplified with two pairs of
primers targeting the same region (close to promoter B) of
110 base pair in length, but specific for the methylated
RFC promoter and the unmethylated promoter respec-
tively as described previously [23]. Primers specific to the
RFC promoter A were designed as shown in Table 1. The
annealing temperature was 58°C for methylated pro-
moter A and 54°C for the unmethylated one. PCR prod-
ucts of 132 bp or 134 bp in length were separated on 2%
agarose gels with ethidium bromide visualization under
UV light. The breast cancer cell lines, MDA-MB-231 and
MCF-7 were used as controls for methylated RFC pro-
moter and unmethylated RFC promoter respectively as
described previously [23].
Quantitative Real-time Methylation Specific PCR
Primers and fluorescent probes based on sodium bisulfite
treatment were designed as shown in Table 1. The RFC
promoter B (minimal sequences: nt.1233–1278) was
flanked by the PCR primers [19]. Fluorescent real-time
PCR was performed in a reaction volume of 50 μl using
components of a Taqman PCR Buffer A Pack (PE Biosys-
tems, Branchburg, NJ). Three microliters of treated
genomic DNA were used in each reaction including 1 ×
Taqman buffer A with 600 nM each primer, 200 nM of
probe, 200 μM of dNTP mix and 5.5 mM MgCl2. Thermal
cycling was carried out on a Bio-Rad iCycler with a dena-
turation step of 95°C for 10 min, 50 cycles of 95°C for 15
s, 60°C for 1 min. Genomic DNA treated with SssI methyl
transferase (New England Biolab, Beverly, MA) was used
as a control for methylated promoter. MYOD1 was used
as internal control because of the lack of CpG sites on the
primers and probe as described previously [31]. Multiple
wells of non-template control were included on each 96-
well PCR plate. All the samples were tested in triplicate for
the RFC and MYOD1 respectively.
Bisulfite Genomic Sequencing
Bisulfite genomic sequencing was used to validate the
results obtained by quantitative real-time MSP in M805,
MDA-MB-231, and MCF-7 cells. Primers flanking RFC
promoter B were designed in regions lacking CpG sites
(Table 1), thus amplification (covering 46 CpG sites) was
independent of methylation status. The 314 bp PCR prod-
uct was separated onto a 1% agarose gel and was purified
with a Gel purification Kit (Qiagen, Valencia, CA). The
PCR product was cloned using a TOPO-PCR TA cloning
vector (Invitrogen, Carlsbad, CA) and at least 10 random
clones were sequenced on an ABI 3100 auto sequencer
with M13 reverse and forward primers.
Table 1: Primers used in methylation specific PCR and bisulfite genomic sequnecing
Methylation Specific PCR (MSP) Annealing positiona
Promoter A (methylated) 58°C 1711–1842
Forward: 5'-TTC GTC GTA GTT TGC GAA TG 1711–1730
Reverse: 5'-CAA CAC GTA CCT AAA CGC GA 1842-1821
Promoter A (unmethylated) 54°C 1710–1843
Forward: 5'-TTT GTT GTA GTT TGT GAA TGG 1710–1730
Reverse: 5'-ACA ACA CAT ACC TAA ACA CAA 1843-1823
Promoter B Ref. [23]
Real-time Quantitative MSP
Promoter B (Methylated) 60°C 1171–1293
Forward: 5'-TTG TCG TAG CGT TCG GTT AC 1171–1190
Reverse: 5'-AAA CTA CAA CGC CCA CAA AA 1293 – 1274
Probe: 5'-Fam-TCG CGG GAC GGA TTC GTT TA 1218–1237
Bisulfite Genomic Sequencing
Promoter B 58°C 1141–1454
Forward: 5'-tgg gtg gga ggg tgt tt 1141–1157
Reverse: 5'-cct cac aaa acc cta caa acc t 1454-1433
a: Numbering is based on NCBI accession number U92868.Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:124 http://www.biomedcentral.com/1471-2407/8/124Statistical analysis
Statistical analysis was performed using a software pack-
age SPCC10 (Chicago, IL). Pearson correlation was used
to assess the association between the promoter methyla-
tion and RFC mRNA levels, and a p < 0.05 was regarded as
statistically significant.
Results
The M805 cell line, obtained from a MFH patient treated
with multiple courses of MTX, developed resistance to
MTX in vivo[25]. A 15-fold resistance to MTX was observed
in M805 cells (IC50 = 2.30 μM) as compared to a fibrosar-
coma cell line, HT1080 (IC50 = 0.15 μM). In contrast,
these two cell lines were almost equally sensitive to TMTX
(IC50: 24 nM for M805 and 19 nM for HT1080, respec-
tively), which enters cells through passive diffusion. This
suggested that the MTX resistance might be the result of
impaired drug uptake. MTX transport assay was per-
formed as shown in Figure 1. A 3.0, 3.1, and 3.6-fold
decrease of [3H]-MTX uptake in M805 cells was found at
2, 5, and 10 min respectively, as compared to the HT1080
cells. The intracellular concentrations of MTX and MTX
polyglutamates after 24 h incubation were measured as
shown in Table 2. Although the total (N = 1–5) MTX pol-
yglutamates in M805 cells was only about 55% of that in
HT1080 cells in consistent with defective drug transport,
long-chain polyglutamates (N = 3–5) accounted for
54.8% of the polyglutamates in M805 cells as compared
to 39% in HT1080 cells, suggesting that the M805 cell line
did not have impaired MTX polyglutamylation. Using
quantitative real-time RT-PCR, a 5-fold decrease in RFC
mRNA expression was detected in M805 cells as compared
to HT-1080, while there was no detectable RFC mRNA in
MDA-MB-231 cells in consistent with previous report
[23]. The down-regulation of RFC mRNA in M805 cell
was not apparently changed after growing cells for 2 weeks
in folate-free media (Life technologies, Bethesda, MD)
supplemented with 20 nM leucovorin, in stead of stand-
ard media containing 2.3 μM folic acid. To screen for
mutations in the M805 cells, the entire coding region of
the RFC was sequenced, but no mutation was identified.
Heavy promoter methylation was identified to be the
basis for complete silencing of RFC in MDA-MB-231 cells
[23]. MSP was therefore performed in M805 cells in
search for the factors responsible for its RFC down-regula-
tion. As shown in Figure 2, PCR products in length of 132
bp for promoter A, and of 110 bp for promoter B were
amplified in reactions with primers specific for methyl-
ated promoters in the MDA-MB-231 and M805 cells, but
not in the other cell lines analyzed, including CCRF-CEM,
CEM-T, HL60R, M316, MCF-7, and HT1080. Being differ-
ent from the RFC-null MDA-MB-231, promoter methyla-
tion in RFC-low M805 cells was partial, because weak
amplification was also observed in reactions with primers
specific for the unmethylated promoters (Figure 2). After
treatment with 5-aza-2'-deoxycytidine, RFC expression
was increased by 2.9-fold in M805 cells, providing evi-
dence that the partial promoter methylation is a mecha-
nism for the RFC down-regulation in this cell line.
Stable transfection of human RFC cDNA into the RFC-
null, MDA-MB-231 cells restored the sensitivity to MTX by
more than 100 fold (data not shown). Transfection of
RFC cDNA into M805 cells proved to be problematic after
multiple attempts. After the treatment of 5-aza-2'-deoxy-
cytidine, a marginal (1.4-fold) increase of sensitivity to
MTX was observed in M805 cells as compared to the
untreated cells. This was similarly seen in MDA-MB-231
cells, perhaps due to increased MRPs expression after the
treatment as reported previously [23].
To further assess the relationship between the RFC mRNA
expression and promoter methylation, a quantitative
approach was adapted using the methodology developed
by Sidransky et al. as described in the Methods [31]. The
methylation level of the RFC promoter B was determined
to be 50.6% for MDA-MB-231 cells, 21.8% for M805 cells,
0.3% for CCRF-CEM cells, and 0% for MCF-7 cells respec-
tively, as compared to that of the DNA treated with Sss I
methyltransferase in vitro (arbitrarily defined as 100%
methylated). To validate these results, genomic DNA from
MDA-MB-231, M805, and MCF-7 cells was further exam-
ined by bisulfite genomic sequencing. As shown in Figure
3, for MDA-MB-231, 638 out of total 690 (92%) CpG sites
were methylated, and eight out of fifteen (53%) clones
[3H]-MTX uptake in M805 cells and HT1080 cellsFigure 1
[3H]-MTX uptake in M805 cells and HT1080 cells. 
Cells were incubated with 1 μM [3H]-MTX and incubations 
were stopped at indicated time points. For each sample, 
experiments were performed in duplicates for each time 
point. Average value and standard error are shown.
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sites 3–5 are covered by sense primer, site 23 by antisense
primer, and sites 12–15 by the fluorescent probe. When
all these sites are simultaneously methylated, template
will be amplified by real-time MSP.) For M805 cells, 299
out of total 460 (65%) CpG sites (10 clones) were meth-
ylated. Two out of ten (20%) clones sequenced for M805
cells were expected to be amplified by real-time MSP. For
MCF-7 cells, only one out of 506 CpG sites was methyl-
ated. These results are in excellent agreement with the data
obtained by real-time MSP.
This quantitative real-time MSP was further utilized in a
panel of cell lines to determine the extents of promoter
methylation and results are shown in Figure 4. The RFC
mRNA levels were measured by real-time RT-PCR (Figure
4). When the extents of promoter methylation measured
in this panel of cell lines were related to their RFC mRNA
levels, a reverse correlation was obtained (Correlation
coefficient = -0.59, p < 0.05). It revealed that high levels of
promoter methylation were only seen in cell lines with
decreased RFC mRNA expression, such as MDA-MB-231
and M805 cells, but not in any of the cell lines with higher
RFC mRNA expression, including CCRF-CEM, HL60R,
CEM-T, M316, MCF-7, and HT1080 cell lines (Figure 4).
Discussion
Promoter methylation is associated with RFC down-regu-
lation in the M805 cells, which resulted in impaired MTX
uptake and drug resistance. Potential efflux mechanisms
to explain decreased MTX uptake were partially excluded
by the fact that MRP-1 and MRP-2 were not up-regulated
in M805 cells as determined by quantitative real-time RT-
PCR (data not shown). This is consistent with previous
studies performed using immuno-histochemistry [25]. As
reported in the prior study, mutations in the TP53 and Rb
genes are not present in M805 cells, which exclude this as
a possible mechanism of MTX resistance through altera-
tions in cell cycle regulation [3]. The M805 cell line was
resistant to MTX when established from a patient's speci-
men, who received pre-operative chemotherapy, includ-
ing multiple doses of MTX. The breast cell line, MDA-MB-
231, also developed MTX resistance in vivo due to the
complete loss of RFC expression resulting from heavy pro-
moter methylation [23,24]. This suggests that RFC pro-
moter methylation may be a possible mechanism of MTX
resistance developed by tumor cells in vivo. Defective MTX
uptake mediated by the RFC is a common mechanism for
drug resistance in many tissue types, including ALL, oste-
osarcoma, and non-Hodgkin's lymphoma [32]. The role
of promoter methylation and prevalence of it is not yet
widely investigated in these diseases. An obstacle of it is
the current methodology. The regular MSP is sensitive;
however, the result of it is only qualitative. The bisulfite
genomic sequencing with the most accuracy is not a prac-
tical approach for patient samples. The quantitative real-
time MSP developed in the current study appeared to be
both sensitive and consistent with data obtained by
bisulfite genomic sequencing. It is therefore reasonable to
apply it in a bigger setting of patient samples in future
studies.
The implications of multiple promoter usage and hetero-
geneity of RFC transcripts in normal and tumor tissue
remain unclear. In this study, at least for MDA-MB-231
and M805 cell lines, DNA methylation occurred simulta-
neously at both promoter regions. Meanwhile, for the
other cell lines included in this study with higher RFC
mRNA expression, DNA methylation was not seen at
either promoter region (Figure 2). Therefore, the pattern
of promoter methylation in RFC promoter appears to be
in a "both or neither" fashion, given the proximity in dis-
tance between these two promoters. Therefore, promoter
methylation is unlikely involved in the selective usage of
multiple promoters in the RFC transcription. However,
the role of methylation is yet to be determined in relation-
ship with transcriptional activities of other RFC promoters
reported recently [14]. Furthermore, 5-aza-2'-deoxycyto-
sine treatment only marginally reversed MTX resistance in
M805 cells, or similarly in MDA-MB-231 cells [23]. This
suggests that a more specific means of demethylation is
perhaps needed to avoid the up-regulation of genes
involved in the drug efflux system upon treatment.
The quantitative correlation between promoter methyla-
tion and RFC mRNA levels observed in this study is
intriguing. This suggests that the extent of promoter meth-
ylation may directly reflect the promoter activity, perhaps
is a fine mechanism in concert with other regulatory ele-
ments [14], as similarly observed in the tumor suppressor
Table 2: Intracellular MTX Polyglutamates after 24 h incubation with 10 uM 3H-MTX
Cell lines Quantities of MTX polyglutamates (pmol/107 cells)
Na = 1 2 3 4 5 Total Long chain (% of total) MTX(Glu)3–5
M805 60.4 7.9 25.0 38.2 19.5 151.0 82.7 (54.8%)
HT1080 135.0 33.0 54.0 37.0 15.0 274.0 106.0 (39%)
a: Indicates the number of additional glutamate residues.Page 5 of 9
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Methylation specific PCR (MSP) on the RFC promoterFigure 2
Methylation specific PCR (MSP) on the RFC promoter. Promoter methylation was assayed by MSP in a panel of malig-
nant cell lines. Only in the breast cancer cell line MDA-MB-231 and the M805 cells, is there PCR-amplification with the primers 
specific for the methylated RFC promoter A and B, while there is amplification with the primers specific for the unmethylated 
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Bisulfite Genomic SequencingF gure 3
Bisulfite Genomic Sequencing. Bisulfite genomic sequencing was used to validate the methylation levels measured by real-
time quantitative MSP in M805 cells, MDA-MB-231 cells and MCF-7 cells. Sequences of the PCR products (nucleotides no. 
1141–1464, Access number: U92868) are mapped, as all the cytidines except those in CpG dinucleotides are converted to 
uracil (as thymidine in figure) after sodium bisulfite modification. The RFC promoter B is underlined. The number above each 
cytidine in CpG binucleotide (shown in bold) indicates the percentage of methylated cytidines on the respective site, respec-
tively. The numbers in parenthesis indicate total clonies sequenced and total number of methylated cytidines in each cell line 
analyzed.
1141 -TGG GTG GGA GGG TGT TT  C GTG GGG A C G TTT TTG  T C G TAG  C GT T
C G GTT A  C G  C G   C GAG GTT T  C G TTT TTA GGA C G    C GTT  C G  C
GG GA  C GGA TT   C GTT TAT TT   C GTA  GT  C GT   C GGT T   C G T   C G
C G  C GT TTT GTG GG C GTT GTA GTT T  C G GAG TT  C G  C G  TG   C G
C G GGG T   C G GGT T   C G GGA GTT TTA GGG TAG  T  C G TTT   C GT   C G
A GT   C GTA GGT  AT  C GG TGG GGA  A   C G GGG TTA   C GG GG  C G C GTG 
T C G GGG GTT G   C G GGG TGT  TT  C GGG GTT TTG GG GTG AGT G  C G GGG 
C G  C GGG  T  C G AGG TTT GTA GGG TTT TGT GAG G - 1454
M805 (10 clones,  299/460   )
MDA-MB-231 (15 clones, 638/690)











































































































































BMC Cancer 2008, 8:124 http://www.biomedcentral.com/1471-2407/8/124gene APC [31]. The patterns of CpG island methylation
revealed by the bisulfite genomic sequencing in MDA-MB-
231 and M805 cells (Figure 3) suggest that the overall
extent of CpG island methylation is perhaps more impor-
tant than that of specific sites. This is in contrast to the
effect of genetic mutations in the promoter region, which
usually abort the binding sites of transcription factors.
This suggests that the overall compactness of DNA con-
ferred by the promoter methylation is perhaps the deter-
minant of transcription activity in the RFC. Although it is
unknown whether methylation, or gene silencing, occurs
first, DNA methylation is important for the maintenance
of a silenced gene [22]. It is possible that the quantitative
methylation is a means for cells to maintain the RFC
mRNA transcription at a desired level, rather than in a
"whole or none" fashion. A future study including a larger
volume of samples is required to further determine the
role of promoter methylation in the RFC transcription reg-
ulation.
Conclusion
In this study, we have developed a quantitative approach
measuring the extents of RFC promoter methylation. This
study further suggests that promoter methylation is a
potential basis for MTX resistance. The quantitative corre-
lation identified in this panel of malignant cell lines
implies that promoter methylation is a possible mecha-
nism involved in the fine regulation of RFC transcription.
Future study is necessary to clarify the role of promoter
methylation in RFC transcription regulation.
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Correlation between promoter methylation and RFC mRNA levelsFigure 4
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CCRF-CEM (arbitrarily defined as 1), as measured by quanti-
tative real-time RT-PCR. The extents of RFC promoter B 
methylation was shown on the "y" axis as percentage relative 
to that of SssI methyl transferase treated genomic DNA 
(arbitrarily defined as 100%), as measured by quantitative 
real-time MSP. The cell lines (n = 8) are indicated above each 
of the data points, respectively. A reverse correlation (Cor-
relation coefficient = -0.59, p < 0.05) was obtained in this 
























































Relative RFC mRNA Page 8 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:124 http://www.biomedcentral.com/1471-2407/8/124Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
6. Williams FM, Flintoff WF: Isolation of a human cDNA that com-
plements a mutant hamster cell defective in methotrexate
uptake.  J Biol Chem 1995, 270(7):2987-2992.
7. Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V: Molecular
cloning of the human placental folate transporter.  Biochem
Biophys Res Commun 1995, 206(2):681-687.
8. Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer
PS, Cowan KH: Isolation of a gene encoding a human reduced
folate carrier (RFC1) and analysis of its expression in trans-
port-deficient, methotrexate-resistant human breast cancer
cells.  Cancer Res 1995, 55(17):3790-3794.
9. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravin-
dranath Y, Matherly LH: Reduced folate carrier gene expression
in childhood acute lymphoblastic leukemia: relationship to
immunophenotype and ploidy.  Clin Cancer Res 1998,
4(9):2169-2177.
10. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar
M, Flintoff WF, Bertino JR: Defective transport is a common
mechanism of acquired methotrexate resistance in acute
lymphocytic leukemia and is associated with decreased
reduced folate carrier expression.  Blood 1997,
89(3):1013-1018.
11. Ma D, Huang H, Moscow JA: Down-regulation of reduced folate
carrier gene (RFC1) expression after exposure to meth-
otrexate in ZR-75-1 breast cancer cells.  Biochem Biophys Res
Commun 2000, 279(3):891-897.
12. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR,
Gorlick R: Mechanisms of methotrexate resistance in oste-
osarcoma.  Clin Cancer Res 1999, 5(3):621-627.
13. Whetstine JR, Flatley RM, Matherly LH: The human reduced
folate carrier gene is ubiquitously and differentially
expressed in normal human tissues: identification of seven
non-coding exons and characterization of a novel promoter.
Biochem J 2002, 367(Pt 3):629-640.
14. Matherly LH, Hou Z, Deng Y: Human reduced folate carrier:
translation of basic biology to cancer etiology and therapy.
Cancer Metastasis Rev 2007, 26(1):111-128.
15. Zhang L, Wong SC, Matherly LH: Transcript heterogeneity of
the human reduced folate carrier results from the use of
multiple promoters and variable splicing of alternative
upstream exons.  Biochem J 1998, 332 ( Pt 3):773-780.
16. Tolner B, Roy K, Sirotnak FM: Structural analysis of the human
RFC-1 gene encoding a folate transporter reveals multiple
promoters and alternatively spliced transcripts with 5' end
heterogeneity.  Gene 1998, 211(2):331-341.
17. Williams FM, Flintoff WF: Structural organization of the human
reduced folate carrier gene: evidence for 5' heterogeneity in
lymphoblast mRNA.  Somat Cell Mol Genet 1998, 24(3):143-156.
18. Gong M, Cowan KH, Gudas J, Moscow JA: Isolation and charac-
terization of genomic sequences involved in the regulation of
the human reduced folate carrier gene (RFC1).  Gene 1999,
233(1-2):21-31.
19. Whetstine JR, Matherly LH: The basal promoters for the human
reduced folate carrier gene are regulated by a GC-box and a
cAMP-response element/AP-1-like element. Basis for tissue-
specific gene expression.  J Biol Chem 2001, 276(9):6350-6358.
20. Whetstine JR, Witt TL, Matherly LH: The human reduced folate
carrier gene is regulated by the AP2 and sp1 transcription
factor families and a functional 61-base pair polymorphism.
J Biol Chem 2002, 277(46):43873-43880.
21. Bird A: DNA methylation patterns and epigenetic memory.
Genes Dev 2002, 16(1):6-21.
22. Jones PA, Baylin SB: The fundamental role of epigenetic events
in cancer.  Nat Rev Genet 2002, 3(6):415-428.
23. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P: Methyla-
tion-dependent silencing of the reduced folate carrier gene
in inherently methotrexate-resistant human breast cancer
cells.  J Biol Chem 2001, 276(43):39990-40000.
24. Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH:
Reduced folate carrier gene (RFC1) expression and anti-
folate resistance in transfected and non-selected cell lines.
Int J Cancer 1997, 72(1):184-190.
25. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y,
Jimeno J, Faircloth G, Bertino JR: Sensitivity of soft tissue sar-
coma cell lines to chemotherapeutic agents: identification of
ecteinascidin-743 as a potent cytotoxic agent.  Clin Cancer Res
2001, 7(9):2908-2911.
26. Dedhar S, Hartley D, Goldie JH: Increased dihydrofolate reduct-
ase activity in methotrexate-resistant human promyelo-
cytic-leukaemia (HL-60) cells. Lack of correlation between
increased activity and overproduction.  Biochem J 1985,
225(3):609-617.
27. Mini E, Moroson BA, Franco CT, Bertino JR: Cytotoxic effects of
folate antagonists against methotrexate-resistant human
leukemic lymphoblast CCRF-CEM cell lines.  Cancer Res 1985,
45(1):325-330.
28. Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Baner-
jee D, Bertino JR, Gorlick R: mRNA expression levels of E2F
transcription factors correlate with dihydrofolate reductase,
reduced folate carrier, and thymidylate synthase mRNA
expression in osteosarcoma.  Mol Cancer Ther 2003,
2(6):535-541.
29. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH:
Impaired membrane transport in methotrexate-resistant
CCRF-CEM cells involves early translation termination and
increased turnover of a mutant reduced folate carrier.  J Biol
Chem 1999, 274(15):10388-10394.
30. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH,
Huvos AG, Meyers PA, Gorlick R: The folate receptor alpha is
frequently overexpressed in osteosarcoma samples and
plays a role in the uptake of the physiologic substrate 5-
methyltetrahydrofolate.  Clin Cancer Res 2007, 13(9):2557-2567.
31. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles
J, Danenberg PV, Yang S, Sidransky D: Quantitative adenomatous
polyposis coli promoter methylation analysis in tumor tis-
sue, serum, and plasma DNA of patients with lung cancer.
Cancer Res 2002, 62(2):371-375.
32. Ferreri AJ, Dell'Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D,
Pasini F, Ambrosetti A, Orvieto E, Ferrarese F, Arrigoni G, Foppoli M,
Reni M, Gaidano G: Aberrant methylation in the promoter
region of the reduced folate carrier gene is a potential mech-
anism of resistance to methotrexate in primary central
nervous system lymphomas.  Br J Haematol 2004,
126(5):657-664.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/124/pre
pubPage 9 of 9
(page number not for citation purposes)
